Parkinson’s disease may cost China 473 billion yuan by 2040

Parkinson’s disease has long been understood as a devastating condition for the individuals who live with it and the families who care for them. Now, a groundbreaking macroeconomic analysis reveals that the true cost of the disease extends far beyond hospital bills and caregiving expenses, rippling through the entire economy of the world’s most populous nation. According to a new study published in Science Bulletin, Parkinson’s disease could impose a cumulative economic burden of approximately 473 billion CNY on China between 2020 and 2040, measured in constant 2024 prices. That staggering figure, equivalent to roughly 0.017 percent of China’s projected gross domestic product over the two-decade span, or about 329 CNY for every person in the country, represents one of the most comprehensive attempts yet to quantify how a single neurodegenerative disease can reshape the trajectory of national and regional economic growth.

The research, led by Dr. Maigeng Zhou of the National Center for Chronic and Noncommunicable Disease Control and Prevention at the Chinese Center for Disease Control and Prevention, in collaboration with Professor Simiao Chen of Heidelberg University and Peking Union Medical College, deployed a sophisticated analytical tool known as a health-augmented macroeconomic model, or HMM. Unlike conventional cost-of-illness studies, which typically tally up direct medical expenditures and short-term productivity losses, the HMM traces the dynamic, compounding pathways through which disease erodes economic output over time. The team applied this model across all 31 mainland provinces of China, drawing on multiple data sources to project how Parkinson’s disease will interact with demography, labor markets, savings behavior, and capital formation through 2040.

The methodological innovation at the heart of the study lies in its treatment of the economy as an interconnected system rather than a simple ledger of costs. Parkinson’s disease is a progressive neurological disorder that impairs movement, cognition, and daily functioning, and its effects multiply as China’s population ages. The model captures several distinct but linked channels of economic damage. First, deaths caused by Parkinson’s disease directly shrink the labor force, removing workers from productive employment permanently. Second, among surviving patients, disability triggers a cascade of labor market consequences: earlier retirement, reduced labor force participation, increased absenteeism, fewer working hours, and diminished productivity on the job. Together, these effects weaken what economists call human capital accumulation, the stock of skills and productive capacity embodied in the workforce.

But the third pathway proved to be the most consequential, and it is one that traditional studies have largely overlooked. Treatment expenditures for Parkinson’s disease divert household and social resources away from savings and productive investment in areas such as education and infrastructure. When families spend more on medications, physician visits, and long-term care, they save less. When national health systems absorb growing treatment costs, fewer resources flow toward capital formation. This slowdown in physical capital accumulation compounds over time: less investment today means a smaller productive base tomorrow, which in turn means lower GDP, reduced income, and ultimately less capacity for future saving and investment. The HMM’s ability to model these cumulative, self-reinforcing feedback loops is precisely what distinguishes its estimates from conventional accounting approaches.

The headline finding is striking in its magnitude, but the provincial breakdown reveals an even more nuanced picture of geographic inequality. Jiangsu, one of China’s most economically advanced provinces, faces the largest absolute projected loss at approximately 42 billion yuan, followed by Guangdong at 36 billion yuan and Shandong at 35 billion yuan. These figures reflect the sheer size and productivity of these provincial economies, where even modest reductions in labor supply and capital accumulation translate into enormous absolute sums. Yet absolute losses tell only part of the story. When burden is measured relative to provincial GDP, a different geography emerges: Heilongjiang, a northeastern province grappling with both industrial decline and rapid population aging, faces the highest relative burden at 0.029 percent of its projected GDP. Meanwhile, Shanghai, China’s financial hub, records the highest per capita burden at 868 yuan per resident.

Perhaps the most intellectually significant finding of the study concerns the relative weight of the different economic pathways. In most provinces, the researchers found, slower physical capital accumulation accounts for a larger share of the total economic loss than reduced labor supply. This is a genuinely counterintuitive result for anyone who assumes that the economic cost of disease flows primarily through missed workdays and early retirements. The finding suggests that the invisible diversion of resources from investment to treatment and care may be the dominant engine of macroeconomic damage, at least for a disease like Parkinson’s that imposes heavy, prolonged caregiving and treatment burdens on a largely elderly population. The implication for policymakers is profound: interventions that reduce treatment costs or delay disability could generate economic returns that far exceed their health benefits alone, by preserving the investment channel that fuels long-term growth.

The study also uncovered important heterogeneity in how disease burden translates into economic loss across different regional contexts. Provinces with more disability-adjusted life years, a composite measure combining years of life lost and years lived with disability, tended to face greater economic losses. However, the researchers observed that this relationship was not uniform. Local economic conditions and patterns of health-care utilization shaped how strongly disease burden converted into macroeconomic damage. In wealthier provinces with more developed health systems, patients may receive more intensive treatment, driving up direct costs but potentially preserving labor capacity. In poorer provinces with limited neurological services, underdiagnosis and inadequate care may suppress measured treatment costs while allowing disability to progress unchecked, weakening labor supply in ways that are harder to see but no less damaging to the economy.

The policy implications flow directly from this regional variation, and the researchers were explicit in arguing against a one-size-fits-all national response. Areas with limited neurological services, they suggest, may benefit most from earlier recognition of Parkinson’s symptoms, reliable access to essential medicines, stronger referral systems, and better continuity of care. In such regions, relatively modest investments in primary care capacity could yield outsized returns by catching the disease before it produces disabling complications. By contrast, economically developed provinces facing large absolute losses may need a different toolkit: preventing disability through earlier and more aggressive disease management, expanding rehabilitation services, optimizing specialist care, and improving the management of advanced disease. The study’s core message is that a regional approach, calibrated to local disease burden, economic capacity, and health-care resources, could simultaneously reduce the human toll of Parkinson’s disease and blunt its longer-term economic consequences.

The timing of this research could hardly be more significant. China is aging at a pace unmatched in human history, with hundreds of millions of people expected to be over the age of 65 by mid-century. Parkinson’s disease, whose prevalence rises steeply with age, is poised to become one of the defining health challenges of this demographic transition. Previous studies in China have largely focused on direct medical spending or the short-term costs borne by patients and families, leaving a critical blind spot: virtually nothing was known about how the disease might affect regional macroeconomic growth over the long run. By filling that gap, the study provides national and provincial policymakers with a quantitative foundation for planning that integrates health policy with economic strategy, rather than treating them as separate domains.

Beyond its immediate relevance to China, the study offers a template for how the global health community thinks about neurodegenerative disease. Cost-of-illness studies, however valuable, capture a static snapshot; macroeconomic models capture the moving picture, in which today’s treatment costs become tomorrow’s capital shortfalls and lost growth. As populations age across East Asia, Europe, and North America, the economic stakes of diseases like Parkinson’s will only grow. The Chinese experience documented in this study suggests that governments everywhere may be systematically underestimating the true cost of neurodegenerative disease, not because the medical costs are hidden, but because the slow leakage of resources away from savings, investment, and productivity operates beneath the threshold of conventional economic accounting. Making that leakage visible, province by province and pathway by pathway, may prove to be the study’s most enduring contribution, transforming Parkinson’s disease from a purely medical challenge into a matter of national economic planning.